Castle Biosciences has appointed Bradley Cole to its board of directors. Cole currently serves as Genomic Health's CFO. In addition, Cole served as both chief operating officer and CFO at the firm. Previously, Cole served as VP of finance and business development for the Endovascular Solutions Group at Guidant. Prior to that, he served as VP and general manager of the vascular surgery business unit of Guidant. Previously, he served as CFO at Endovascular Technologies until it was acquired by Guidant in 1997. Before Endovascular, he served as CFO at Applied Biosystems until 1994.